Theriva Biologics KOL Event on Advancing Unique Oncolytic Virus Therapeutics

Back to Events


Join us for a discussion with immunotherapy expert Michael Aaron Morse, MD (Duke University School of Medicine), who will provide an overview of the oncolytic virus landscape and the encouraging data that positions Theriva Biologics’ novel oncolytic adenovirus (OV) platform at the forefront of development to address devastating cancers with high unmet need. The discussion will also include recent findings from independent research highlighting the market opportunities for pancreatic ductal adenocarcinoma (PDAC).

VCN-01, Theriva’s lead clinical-stage drug candidate, is an intravenous, oncolytic adenovirus designed to break down the tumor stroma. Theriva Biologics’ upcoming Phase 2 clinical trial, VIRAGE, will evaluate VCN-01 in combination with standard-of-care chemotherapy gemcitabine/nab-paclitaxel in patients with PDAC.

An audience Q&A session will follow the formal discussion.

The post Theriva Biologics KOL Event on Advancing Unique Oncolytic Virus Therapeutics appeared first on LifeSci Events.